<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38574363</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-233X</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Obstetrics and gynecology</Title><ISOAbbreviation>Obstet Gynecol</ISOAbbreviation></Journal><ArticleTitle>Premature Ovarian Insufficiency After Coronavirus Disease 2019 (COVID-19): Autoimmune Follicle-Stimulating Hormone (FSH) and FSH Receptor Blockade.</ArticleTitle><Pagination><StartPage>e149</StartPage><EndPage>e152</EndPage><MedlinePgn>e149-e152</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/AOG.0000000000005574</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since the onset of the coronavirus disease (COVID-19) pandemic, a variety of long-COVID-19 symptoms and autoimmune complications have been recognized.</AbstractText><AbstractText Label="CASES" NlmCategory="METHODS">We report three cases of autoimmune premature poor ovarian response in patients aged 30-37 years after mild to asymptomatic COVID-19 before vaccination, with nucleotide antibody confirmation. Two patients failed to respond to maximum-dose gonadotropins for more than 4 weeks, despite a recent history of response before having COVID-19. After a month of prednisone 30 mg, these two patients had normal follicle-stimulating hormone (FSH) levels, high oocyte yield, and blastocyst formation in successful in vitro fertilization cycles. All three patients have above-average anti-m&#xfc;llerian hormone levels that persisted throughout their clinical ovarian insufficiency. Two patients had elevated FSH levels, perhaps resulting from FSH receptor blockade. One patient, with a history of high response to gonadotropins 75 international units per day and below-normal FSH levels, had no ovarian response to more than a month of gonadotropins (525 international units daily), suggesting autoimmune block of the FSH glycoprotein and possible FSH receptor blockade.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Auto-antibody production in response to COVID-19 before vaccination may be a rare cause of autoimmune poor ovarian response. Although vaccination is likely protective, further study will be required to evaluate the effect of vaccination and duration of autoimmune FSH or FSH receptor blockade.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>New York Medical College, the Department of Obstetrics and Gynecology, New York Medical College, and Reproductive Endocrinology, Westchester Medical Center, Valhalla, and Westmed Reproductive Services, Purchase, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bibi</LastName><ForeName>Moses</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Keltz</LastName><ForeName>Martin D</ForeName><Initials>MD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Obstet Gynecol</MedlineTA><NlmUniqueID>0401101</NlmUniqueID><ISSNLinking>0029-7844</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9002-68-0</RegistryNumber><NameOfSubstance UI="D005640">Follicle Stimulating Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011962">Receptors, FSH</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005640" MajorTopicYN="N">Follicle Stimulating Hormone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016649" MajorTopicYN="Y">Primary Ovarian Insufficiency</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011962" MajorTopicYN="Y">Receptors, FSH</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Financial Disclosure The authors did not report any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>16</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>4</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>4</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38574363</ArticleId><ArticleId IdType="doi">10.1097/AOG.0000000000005574</ArticleId><ArticleId IdType="pii">00006250-990000000-01051</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ehrenfeld M, Tincani A, Andreoli L, Cattalini M, Greenbaum A, Kanduc D, et al. COVID-19 and autoimmunity. Autoimmun Rev 2020;19:102597. doi: 10.1016/j.autrev.2020.102597</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102597</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun 2021;12:5417. doi: 10.1038/s41467-021-25509-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Marques O, Halpert G, Schimke LF, Ostrinski Y, Vojdani A, Baiocchi GC, et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat Commun 2022;13:1220. doi: 10.1038/s41467-022-28905-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-28905-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K, Chen G, Hou H, Liao Q, Chen J, Bai H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online 2021;42:260&#x2013;7. doi: 10.1016/j.rbmo.2020.09.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rbmo.2020.09.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelan N, Behan LA, Owens L. The impact of the COVID-19 pandemic on women's reproductive health. Front Endocrinol 2021;12:642755. doi: 10.3389/fendo.2021.642755</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.642755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins J, Al-Inizi S. Premature ovarian insufficiency secondary to COVID-19 infection: an original case report. Int J Gynaecol Obstet 2021;154:179&#x2013;80. doi: 10.1002/ijgo.13719</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijgo.13719</ArticleId></ArticleIdList></Reference><Reference><Citation>Madaan S, Jaiswal A, Kumar S, Talwar D, Halani D. Premature ovarian failure: a long COVID sequelae. Med Sci 2021:25:1286&#x2013;90.</Citation></Reference><Reference><Citation>Puca E, Puca E. Premature ovarian failure related to SARS-CoV-2 infection. J Med Cases 2022;13:155&#x2013;8. doi: 10.14740/jmc3791</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jmc3791</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanei M, Solaymani-Dodaran M, Qazvini A, Ghazale AH, Setarehdan SA, Saadat SH, et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respir Res 2021;22:245. doi: 10.1186/s12931-021-01833-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-021-01833-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, et al. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med 2021;47:521&#x2013;37. doi: 10.1007/s00134-021-06394-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06394-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel N, Goyal N, Nagaraja R, Kumar R. Systemic corticosteroids for management of &#x201c;long-COVID&#x201d;: an evaluation after 3 months of treatment. Monaldi Arch Chest Dis 2021;92. doi: 10.4081/monaldi.2021.1981</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2021.1981</ArticleId></ArticleIdList></Reference><Reference><Citation>Utrero-Rico A, Ruiz-Ruig&#xf3;mez M, Laguna-Goya R, Arrieta-Ortubay E, Chivite-Lacaba M, Gonz&#xe1;lez-Cuadrado C, et al. A short corticosteroid course reduces symptoms and immunological alterations underlying long-COVID. Biomedicines 2021;9:1540. doi: 10.3390/biomedicines9111540</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9111540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>